Advertisement

Reactions Weekly

, Volume 1714, Issue 1, pp 230–230 | Cite as

Infliximab

Various toxicities: 5 case reports
Case report
  • 9 Downloads

Reference

  1. Ratnakumaran R, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scandinavian Journal of Gastroenterology 53: 700-707, No. 6, Jun 2018. Available from: URL: http://doi.org/10.1080/00365521.2018.1464203 -United KingdomCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations